Hug E B, Adams J, Fitzek M, De Vries A, Munzenrider J E
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):979-84. doi: 10.1016/s0360-3016(00)00545-9.
Most children with orbital rhabdomyosarcoma will survive their disease. However, conventional photon-radiation treatment, as part of multimodality therapy, results in varying degrees of long-term functional and cosmetic side effects. This report introduces external beam proton radiation therapy (PRT) as a conformal, three-dimensional planned radiation technique for this disease, analyzes normal tissue dosimetry, and describes the technique's application in the first 2 patients.
Between January 1995 and February 1996, 2 patients underwent PRT following biopsy and chemotherapy for orbital rhabdomyosarcoma. Fifty and 55 Cobalt Gray Equivalent (CGE) were delivered to the gross tumor volume and 40 CGE to clinical target volumes in both patients. A relative biologic effectiveness (RBE) of 1.1 was utilized to correlate proton dose calculations with CGE. To achieve dose conformity, a "patch technique" was utilized, where target regions were divided into segments, each treated by a separate proton field. Dose-volume histograms were obtained for target and nontarget regions, including lens, bony orbit, pituitary gland, optic chiasm, optic nerves, lacrimal gland, and ipsilateral frontal and temporal lobes.
At 3.4 and 2.5 years after PRT, both patients are clinically and radiographically free of disease. Visual acuity remains excellent, without signs of cataract formation; pituitary function is normal; cosmetically, only mild enophthalmos is noticeable. Doses to 90%, 50%, and 5% of lens volume were kept at less than 1%, less than 2%, and less than 8%, respectively. Fifty percent of lacrimal gland volume received less than 36% of the prescribed dose and 50% of the volume of the optic chiasm, pituitary gland, and hypothalamus were restricted to less than 2%. Proton conformity to orbital contents resulted in between 9% and 36% of the prescribed dose reaching the ipsilateral temporal and frontal lobes immediately adjacent to bony orbit (5% volume).
PRT can offer excellent sparing of lens and selected intraorbital and ocular normal structures, while maintaining conformal target-dose coverage. The steep dose gradient beyond the orbit minimizes irradiation of normal brain parenchyma, with almost complete sparing of the pituitary gland. Reduction of integral irradiation exposure of the periorbital region will, hopefully, reduce the risk of second malignancy later in life. Reduced radiation dose to specific organs in close proximity to, but not part of the target region promises improved functional outcome and better cosmesis for childhood cancer survivors.
大多数眼眶横纹肌肉瘤患儿能战胜疾病存活下来。然而,作为多模式治疗一部分的传统光子放射治疗会导致不同程度的长期功能和美容方面的副作用。本报告介绍了外照射质子放射治疗(PRT)作为针对该疾病的一种适形、三维计划的放射技术,分析了正常组织剂量测定,并描述了该技术在前两名患者中的应用。
1995年1月至1996年2月期间,2例眼眶横纹肌肉瘤患者在活检和化疗后接受了PRT。两名患者的大体肿瘤体积均接受了50和55钴灰当量(CGE)的照射,临床靶体积接受了40 CGE的照射。利用相对生物效应(RBE)值1.1将质子剂量计算与CGE相关联。为实现剂量适形,采用了“贴片技术”,即将靶区域分成多个部分,每个部分由单独的质子野进行治疗。获取了靶区和非靶区的剂量体积直方图,包括晶状体、眼眶骨、垂体、视交叉、视神经、泪腺以及同侧额叶和颞叶。
PRT后3.4年和2.5年时,两名患者临床和影像学上均无疾病。视力保持极佳,无白内障形成迹象;垂体功能正常;在美容方面,仅可见轻度眼球内陷。晶状体体积的90%、50%和5%所接受的剂量分别保持在1%以下、2%以下和8%以下。泪腺体积的50%接受的剂量低于规定剂量的36%,视交叉、垂体和下丘脑体积的50%所接受的剂量限制在2%以下。质子对眼眶内容物的适形性导致规定剂量的9%至36%到达紧邻眼眶骨(5%体积)的同侧颞叶和额叶。
PRT能很好地保护晶状体以及选定的眶内和眼部正常结构,同时保持适形的靶区剂量覆盖。眼眶外陡峭的剂量梯度使正常脑实质的照射减至最小,垂体几乎完全得到保护。希望眶周区域整体照射暴露的减少能降低日后发生第二原发恶性肿瘤的风险。对紧邻但不属于靶区的特定器官减少辐射剂量有望改善儿童癌症幸存者的功能结局并获得更好的美容效果。